Maxim Group reiterated their buy rating on shares of Applied DNA Sciences (NASDAQ:APDN) in a research note published on Friday morning, TipRanks reports. They currently have a $18.00 price objective on the technology company’s stock.
Several other research firms have also weighed in on APDN. HC Wainwright reduced their price objective on Applied DNA Sciences from $14.00 to $13.00 and set a buy rating on the stock in a research note on Wednesday, April 28th. Zacks Investment Research upgraded Applied DNA Sciences from a sell rating to a hold rating in a report on Monday, May 10th. Finally, Roth Capital initiated coverage on Applied DNA Sciences in a report on Friday, February 12th. They set a buy rating and a $24.00 target price on the stock.
NASDAQ APDN opened at $6.35 on Friday. The firm has a market capitalization of $47.45 million, a P/E ratio of -1.84 and a beta of 1.40. Applied DNA Sciences has a 1-year low of $4.95 and a 1-year high of $14.84. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.13 and a quick ratio of 2.01. The business’s 50-day simple moving average is $6.71 and its 200-day simple moving average is $7.89.
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Applied DNA Sciences by 2.5% during the 1st quarter. BlackRock Inc. now owns 89,526 shares of the technology company’s stock valued at $643,000 after buying an additional 2,207 shares during the period. Orion Portfolio Solutions LLC purchased a new stake in Applied DNA Sciences during the 4th quarter worth approximately $65,000. Golden Green Inc. purchased a new stake in Applied DNA Sciences during the 4th quarter worth approximately $70,000. Premier Asset Management LLC purchased a new stake in Applied DNA Sciences during the 1st quarter worth approximately $144,000. Finally, Creative Planning increased its holdings in Applied DNA Sciences by 39.1% during the 4th quarter. Creative Planning now owns 81,145 shares of the technology company’s stock worth $414,000 after purchasing an additional 22,794 shares during the last quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.
Applied DNA Sciences Company Profile
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia.
Read More: Price Target
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.